Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates

被引:79
作者
Malini, B
Purohit, A
Ganeshapillai, D
Woo, LWL
Potter, BVL
Reed, MJ
机构
[1] St Marys Hosp, Imperial Coll Sch Med, London W2 1NY, England
[2] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England
关键词
steroid sulphatase activity; pharmacophore; inhibitor;
D O I
10.1016/S0960-0760(00)00178-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The identification of the active pharmacophore: required for potent inhibition of steroid sulphatase activity, i.e. an aryl-O-sulphamate structure. has led to the synthesis and testing of a large number of 1 . 4 ring-based inhibitors. 4-Methylcoumarin-7-O-sulphamate (COUMATE) was one of the first non-steroid based inhibitors identified. In an attempt to increase the potency of this class of inhibitor a series of tricyclic COURMATEs (665 - 6615 COURMATEs) have been synthesised and evaluated. Using placental microsomes as a source of oestrone sulphatase (EI-STS) the size of the third ring of the tricyclic COUMATEs was found to have a marked effect on inhibitor potency. Whereas 665- and 6615-COUMATEs had IC(50)s of 200 and 370 nM. respectively, the most potent inhibitor in vitro in this series was 6610 COUMATE with an IC50 of 1 nM. Selected inhibitors were tested for their in vivo potency by administration of a single close (0.1 or I mg/kg. p.o.) to female rats. Surprisingly, in vivo 6615 COUMATE proved to be the most active drug inhibiting rat liver EI-STS activity by 23 and 94% when assayed 24 h after administration of the 0.1 and 1 mg/kg doses. EI-STS activity in brain tissue and white blood cells was also found to be inhibited when selected drugs were tested. These studies: have identified a number of tricyclic COUMATEs with therapeutic potential. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:253 / 258
页数:6
相关论文
共 25 条
  • [1] Potent inhibition of steroid sulfatase activity by 3-O-sulfamate 17α-benzyl(or 4′-tert-butylbenzyl)estra-1,3,5(10)-trienes:: Combination of two substituents at positions C3 and C17α of estradiol
    Ciobanu, LC
    Boivin, RP
    Luu-The, V
    Labrie, F
    Poirier, D
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (12) : 2280 - 2286
  • [2] ANDROSTENEDIONE AND ANDROST-5-ENE-3-BETA, 17-BETA-DIOL STIMULATE DMBA-INDUCED RAT MAMMARY-TUMORS - ROLE OF AROMATASE
    DAUVOIS, S
    LABRIE, F
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1989, 13 (01) : 61 - 69
  • [3] DAYNES RA, 1993, J IMMUNOL, V150, P5219
  • [4] DAYNES RA, 1990, EUR J CANCER, V30, P1453
  • [5] DUNCAN L, 1993, CANCER RES, V53, P298
  • [6] Elger W, 1998, Expert Opin Investig Drugs, V7, P575, DOI 10.1517/13543784.7.4.575
  • [7] Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application
    Elger, W
    Schwarz, S
    Hedden, AM
    Reddersen, G
    Schneider, B
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 55 (3-4) : 395 - 403
  • [8] FOULKES R, STEROID HORMONES T C, P135
  • [9] Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors
    Li, PK
    Milano, S
    Kluth, L
    Rhodes, ME
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1996, 59 (01) : 41 - 48
  • [10] Development of potent non-estrogenic estrone sulfatase inhibitors
    Li, PK
    Chu, GH
    Guo, JP
    Peters, A
    Selcer, KW
    [J]. STEROIDS, 1998, 63 (7-8) : 425 - 432